Importantly, encouraging results have recently shown that ANGPT2 inhibition restored vascular stability, repressed tumor angiogenesis, and decreased the metastatic burden and proportion of sorafenib tolerance of early or even advanced-stage malignancies [26–28]. This evidence concerns the gene ANGPT2 and neoplasm.